Invesaro

Stocks Health care RGNX

NASDAQ · Health care

REGENXBIO Inc. (RGNX)

REGENXBIO Inc. brought in $174.5M of revenue over the twelve months to June 30, 2026, up 12.0% from a year earlier. It posted a net loss of $196.4M. In fiscal 2025 capital spending exceeded operating cash flow by $126.4M. At June 30, 2026 it held $36.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Revenue (last 12 months)
$174.5M
+12.0% year on year
Net margin
-112.6%

What REGENXBIO Inc. does

REGENXBIO Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker RGNX.

Revenue and profit by year

Revenue
FY18: $218.5M $218.5M FY18FY19: $35.2M $35.2M FY19FY20: $154.6M $154.6M FY20FY21: $470.3M $470.3M FY21FY22: $112.7M $112.7M FY22FY23: $90.2M $90.2M FY23FY24: $83.3M $83.3M FY24FY25: $170.4M $170.4M FY25
Net income
FY18: $99.9M $99.9M FY18FY19: -$94.7M -$94.7M FY19FY20: -$111.3M -$111.3M FY20FY21: $127.8M $127.8M FY21FY22: -$280.3M -$280.3M FY22FY23: -$263.5M -$263.5M FY23FY24: -$227.1M -$227.1M FY24FY25: -$193.9M -$193.9M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$170.4M-$161.2M-$193.9M-$3.76-$126.4M
2024$83.3M-$233.3M-$227.1M-$4.59-$175.6M
2023$90.2M-$268.1M-$263.5M-$6.02-$228.4M
2022$112.7M-$262.9M-$280.3M-$6.50-$238.2M
2021$470.3M$160M$127.8M$2.91$134.7M
2020$154.6M-$119.2M-$111.3M-$2.98-$80.9M

Latest SEC filings

What REGENXBIO Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 23, 2026
    Material agreement 8-K
  2. August 25, 2026
    Executive or director change 8-K
  3. August 24, 2026
    Investor disclosure 8-K
  4. August 6, 2026
    Quarterly report 10-Q · period to June 30, 2026
  5. August 6, 2026
    Quarterly results 8-K
  6. July 20, 2026
    Other event 8-K
  7. July 17, 2026
    Securities offering prospectus 424B5
  8. July 17, 2026
    Offering term sheet FWP
  9. July 16, 2026
    Securities offering prospectus 424B5
  10. July 6, 2026
    Form SC TO-I/A filing SC TO-I/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 3, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about RGNX

What does REGENXBIO Inc. do?

REGENXBIO Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker RGNX.

Is REGENXBIO Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $196.4M on revenue of $174.5M.

How much revenue does REGENXBIO Inc. make?

Over the twelve months to June 30, 2026 REGENXBIO Inc. reported revenue of $174.5M. That is 12.0% more than a year earlier.

When did REGENXBIO Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 23, 2026.

Similar companies

AMGN
Amgen Inc
GILD
Gilead Sciences, Inc.
BIIB
Biogen Inc.
BNTX
BioNTech SE
NBIX
Neurocrine Biosciences Inc
EXEL
Exelixis, Inc.

Follow RGNX

Get an email when REGENXBIO Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow RGNX: get an email when it files

Where the numbers come from

Financial figures are the values REGENXBIO Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.